Retension Pharmaceutical Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • RTSN

Stock Symbol

  • Share Price
  • $13.40
  • (As of Wednesday Closing)

Retension Pharmaceutical General Information

Description

Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1104 West Broad Street
  • Suite 1029
  • Falls Church, VA 22046
  • United States
+1 (703)
Primary Industry
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1104 West Broad Street
  • Suite 1029
  • Falls Church, VA 22046
  • United States
+1 (703)

Retension Pharmaceutical Timeline

202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Retension Pharmaceutical Stock Performance

As of 18-Nov-2026, Retension Pharmaceutical’s stock price is $13.40. Its current market cap is $116M with 8.33M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.40 $11.41 $9.66 - $18.64 $116M 8.33M 148K -$2.61

Retension Pharmaceutical Financials Summary

As of 30-Jun-2026, Retension Pharmaceutical has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024
Revenue 0 0 0
EBITDA (12,559) (6,881) (2,266)
Net Income (11,941) (6,301) (1,910)
Total Assets 16,127 21,445 8,370
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Retension Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Retension Pharmaceutical‘s full profile, request access.

Request a free trial

Retension Pharmaceutical Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Retension Pharmaceutical‘s full profile, request access.

Request a free trial

Retension Pharmaceutical Patents

Retension Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026107071-A1 Combination therapy Pending 14-Nov-2024
US-20260132135-A1 Crystalline form Pending 14-Nov-2024
WO-2026107107-A1 Crystalline form of a pde5 inhibitor Pending 14-Nov-2024
US-12258350-B1 Crystalline forms of 4-ethoxy-n-(2-methoxyethyl)-n-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5, 1-f][1,2,4]triazin-2-yl)benzenesulfonamide Active 14-Nov-2024 C07D487/04

Retension Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Retension Pharmaceutical Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Retension Pharmaceutical‘s full profile, request access.

Request a free trial

Retension Pharmaceutical FAQs

  • When was Retension Pharmaceutical founded?

    Retension Pharmaceutical was founded in 2023.

  • Where is Retension Pharmaceutical headquartered?

    Retension Pharmaceutical is headquartered in Falls Church, VA.

  • What is the size of Retension Pharmaceutical?

    Retension Pharmaceutical has 12 total employees.

  • What industry is Retension Pharmaceutical in?

    Retension Pharmaceutical’s primary industry is Drug Discovery.

  • Is Retension Pharmaceutical a private or public company?

    Retension Pharmaceutical is a Public company.

  • What is Retension Pharmaceutical’s stock symbol?

    The ticker symbol for Retension Pharmaceutical is RTSN.

  • What is the current stock price of Retension Pharmaceutical?

    As of 18-Nov-2026 the stock price of Retension Pharmaceutical is $13.40.

  • What is the current market cap of Retension Pharmaceutical?

    The current market capitalization of Retension Pharmaceutical is $116M.

  • What is Retension Pharmaceutical’s annual earnings per share (EPS)?

    Retension Pharmaceutical’s EPS for 12 months was -$2.61.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process